International audienceThe quantification of very low concentrations of circulating tumor DNA (ctDNA) biomarkers from liquid biopsies has become an important requirement for clinical diagnostics and personalized medicine. In particular, the simultaneous detection of wild-type (WT) dsDNA and their cancer-related counterparts presenting single-point mutations with simple, sensitive, specific, and reproducible technologies is paramount for ctDNA assays in clinical practice. Here, we present the development and evaluation of an amplified dsDNA assay based on a combination of isothermal rolling circle amplification (RCA) and time-gated Förster resonance energy transfer (TG-FRET) between a Tb donor and two dye (Cy3.5 and Cy5.5) acceptors. The RCA–...
Detection of mutated genomic DNA from cancer cells circulating in blood may improve tumor staging an...
International audienceCell‐free plasma DNA (cfDNA) and mimicking circulating tumor cells (mCTCs) hav...
The protein kinase BRAF is one of the key players in regulating cellular responses to extracellular ...
International audienceThe quantification of very low concentrations of circulating tumor DNA (ctDNA)...
International audienceThe quantification of cellular deoxyribonucleoside triphosphate (dNTP) levels ...
BackgroundPersonalized medicine requires accurate molecular profiling for targeted therapy decisions...
Assessment of KRAS status is mandatory in patients with metastatic colorectal cancer (mCRC) before a...
DNA point mutation in a BRAF proto-oncogene, V600E, is considered an important prognostic and predic...
Circulating tumor DNA (ctDNA) analysis is being incorporated into cancer care; notably in profiling ...
INTRODUCTION: Detection and monitoring of circulating tumor DNA (ctDNA) is rapidly becoming a diagno...
International audienceWe used a novel method based on allele-specific quantitative polymerase chain ...
International audienceThe detection of the BRAF V600E mutation in melanoma samples is used to select...
Detection of mutated genomic DNA from cancer cells circulating in blood may improve tumor staging an...
International audienceCell‐free plasma DNA (cfDNA) and mimicking circulating tumor cells (mCTCs) hav...
The protein kinase BRAF is one of the key players in regulating cellular responses to extracellular ...
International audienceThe quantification of very low concentrations of circulating tumor DNA (ctDNA)...
International audienceThe quantification of cellular deoxyribonucleoside triphosphate (dNTP) levels ...
BackgroundPersonalized medicine requires accurate molecular profiling for targeted therapy decisions...
Assessment of KRAS status is mandatory in patients with metastatic colorectal cancer (mCRC) before a...
DNA point mutation in a BRAF proto-oncogene, V600E, is considered an important prognostic and predic...
Circulating tumor DNA (ctDNA) analysis is being incorporated into cancer care; notably in profiling ...
INTRODUCTION: Detection and monitoring of circulating tumor DNA (ctDNA) is rapidly becoming a diagno...
International audienceWe used a novel method based on allele-specific quantitative polymerase chain ...
International audienceThe detection of the BRAF V600E mutation in melanoma samples is used to select...
Detection of mutated genomic DNA from cancer cells circulating in blood may improve tumor staging an...
International audienceCell‐free plasma DNA (cfDNA) and mimicking circulating tumor cells (mCTCs) hav...
The protein kinase BRAF is one of the key players in regulating cellular responses to extracellular ...